One of the original inventors of Generative Flow Networks.

Lead 20+ person drug discovery team at Mila.

Ph.D. with Yoshua Bengio.

‍

Chenghao works at the intersection of generative algorithms and molecular design. Prior to Dreamfold, Chenghao has designed and tested hundreds of molecules/polymers in the wet lab, including de novo designs generated from his own algorithms.

He did his Ph.D. at McGill University and Mila with Dima Perepichka and Yoshua Bengio. He has been awarded the prestigious Vanier scholarship.

DeepMind Professor of AI at Oxford, Former Head of Graph ML Research at Twitter, founder of multiple successful startups, author of major contributions to the field of geometric deep learning for protein design. Michael is an avid opera fan.

Before DreamFold, James worked with Microsoft for nearly 5 years, most recently as an Applied Scientist in the Turing team working on LLMs and web-scale chatbots. Prior to Microsoft, James was a founding Quantitative Analyst for a Toronto-based hedge fund.

James obtained a Bachelors of Engineering in Mathematics and Engineering from Queen's University

Kilian is a machine learning research scientist. His research focuses on generative models for protein backbone generation. Before joining DreamFold, he was a postdoctoral fellow at Mila and McGill University where he worked on distribution shifts, generative modelling and optimal transport.

Kilian holds a PhD from IRISA-INRIA (France). His research focused on the interaction of optimal transport and deep learning, especially on the use of minibatch optimal transport in deep learning applications.

Steve is an expert in protein engineering with over 20 years of experience in the design and development of antibody, cytokine, and fusion protein drugs. After receiving a PhD in Cell Biology at Johns Hopkins University School of Medicine and postdoctoral training at UC Berkeley, he held positions at successful biotech companies including Director Cell Biology at Exelixis and was VP Research at Xencor, FivePrime Therapeutics, and Xoma. He most recently served as Chief R&D Officer at Nektar Therapeutics and is now an independent consultant to the biotechnology industry. Steve sits on the Board of Directors of Forte Biosciences, and the Biotechnology Advisory Board of the University of Delaware.